Male Female Lec Seniority FINAL 1.10.10.xlsx - SSA Punjab

TRIAL ID: PRIMA19 REFERENCES• Bordeleau L, Berinstein NL. Molecular diagnostics in follicular non-Hodgkin's lymphoma: a review. SeminOncol. 2000; 27 (Suppl 12):42-52.• Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, et al. Rituximab therapy inhaematologic malignancy patients with circulating blood tumor cells: association with increased infusionrelatedside effects and rapid blood tumor clearance. J Clin Oncol 1999; 17:791–5.• Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, and al. Report of an internationalworkshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999; 17:1244–53.• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G,Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared withCHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:235-242• Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, and al. Rituximab (anti-CD20monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumorburden: clinical and molecular evaluation. Blood 2001; 97:101–106.• Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, and al. Treatment ofpatients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibodyand CHOP chemotherapy. J Clin Oncol 1999; 17:268–76.• Czuczman MS, Grillo-Lopez AJ LoBuglio AI, Gordon LI, Starostik P, Dowden S, Alkuzweny B, Allen RS.Patients with Low-Grade NHL Treated with Rituximab + CHOP Experience Prolonged Clinical andMolecular Remission. ASH 2003, abstract 1493.• Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME,Mohrbacher A, Weaver R, Dowden S, Levy R. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999; 17:1851-1857• Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J ClinOncol 2000; 18:3135–43.• Demidem A, Lam T, Alan S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8)monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. CancerBiotherapy and Radiopharmaceuticals 1997; 12:177-186.• Dreyling M, Forstpointner R, Repp R, Herrmann S, Haenel A, Metzner B, Pott C, Hartmann F, RothmannF, Parwaresch R, Unterhalt M, Hiddemann W. Combined immuno-chemotherapy (R-FCM) results insuperior remission and survival rates in recurrent follicular and mantle cell lymphoma - final results of aprospective randomized trial of the GLSG. Annual Meeting of the American Society of Haematology, SanDiego. Blood 102, No. 11: (2003)• Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, Malpas JS, Lister TA.Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986; 4:1470-80.• Ghielmini M, Hsu Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, BetticherDC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M,Vorobiof D, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantlyincreases event-free survival and response duration compared with the standard weekly x 4 schedule.Blood. 2004; 103:4416-4423• Gregory SA, Venugopal P, Adler S, Enschede S, Yunus F, O'Brien TM, O'Donnell KF, Robin EL.Combined Fludarabine, Mitoxantrone, and Rituximab Achieves a High Response as Initial Treatment forAdvanced Low Grade Non-Hodgkin's Lymphoma (LGNHL). Blood. 2002; 100:(abstr 1401).• Hainsworth JD, Burris III HA, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemictherapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000;95:3052-3056.• Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA.Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J ClinOncol. 2002; 20:4261-7.• Hainsworth JD, Litchy S, Greco FA. Scheduled Rituximab Maintenance Therapy Versus RituximabRetreatment at Progression in Patients with Indolent Non-Hodgkin's Lymphoma (NHL) Responding toSingle-Agent Rituximab: A Randomized Trial of the Minnie Pearl Cancer Research Network. ASH 2003,abstract 231.• Herold M, Dölken G, Fiedler F et al. Ongoing clinical studies – randomized phase III study for thetreatment of advanced indolent NHL and MCL:chemotherapy versus chemotherapy plus Rituximab. AnnHematol. 2003; 82:77–79.• Hiddemann W, Unterhalt M. Stand und Perspektiven in der Therapie follikulärer Keimzentrumslymphome.Dt Ärzteblatt 1998; 95:3209–3216.Version 5.1 – 4 December 2008 PRIMA protocol Page 53/74